Skip to main content
Dennis Citrin, MD, Oncology, Zion, IL, City of Hope Chicago

DennisLCitrinMD

Oncology Zion, IL

Breast Cancer, Cancer Genetics/Cancer Risk Assessment

Physician

Dr. Citrin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Citrin's full profile

Already have an account?

Summary

  • Dr. Dennis Citrin is an oncologist in Chicago, IL He received his medical degree and PhD from University of Glasgow Faculty of Medicine and has been in practice 48 years. He has served on the faculty of several medical schools, and is currently on faculty of Rosalind Franklin School of Medicine. He specializes in breast cancer.

Education & Training

  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1976 - 1977
  • University of Glasgow Faculty of Medicine
    University of Glasgow Faculty of MedicineClass of 1969

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2020 - 2026
  • IL State Medical License
    IL State Medical License 1982 - 2026
  • WI State Medical License
    WI State Medical License 1977 - 1981
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Who, When, Why: Navigating Complex Breast Cancer Screening Guidelines
    Who, When, Why: Navigating Complex Breast Cancer Screening GuidelinesFebruary 17th, 2022
  • Omicron Variant Makes Itself Known over Holiday Weekend • Systems Partner to Promote Health Care Careers • NorthShore Program Encourages Genetic Screening
    Omicron Variant Makes Itself Known over Holiday Weekend • Systems Partner to Promote Health Care Careers • NorthShore Program Encourages Genetic ScreeningNovember 29th, 2021
  • Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer
    Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast CancerJanuary 22nd, 2021
  • Join now to see all

Hospital Affiliations